47results about How to "Improve depressive symptoms" patented technology

Provided is a superior, novel heterocyclic compound with improved solubility in oil such as sesame oil and benzyl benzoate, which has a broader treatment spectrum, causes less side effects, and is superior in tolerability and safety, and use thereof. A heterocyclic compound represented by the formula (I) wherein each symbol is as defined in the specification, or a salt thereof.

The present invention comprises novel methods for the use of compositions comprising 7-keto DHEA for treating psychiatric conditions. These methods include administering an effective amount of a composition comprising 7-keto DHEA in an acceptable carrier, alone or in combination with other psychiatric drugs, such as analgesic agents, anticonvulsants, anti-anxiety agents, antidepressants, anti-panic agents, antipsychotic agents, bipolar agents, psychostimulants to reduce or ameliorate symptoms of a psychiatric condition. This method may be used alone or as an adjunctive treatment for treating a wide variety of psychiatric conditions such as stress disorders, anxiety disorders and depressive disorders.

A light exposure device (20) for improving cognitive symptoms and depression symptoms is characterized in imparting photostimulation to the retina by continuous flashing of a light source (21) at a frequency of 1 to 10 Hz and by photostimulation, inducing the continuous expression of Homer 1a and activation of the BK-type potassium channels in pyramidal cells of the cerebral cortex. It is possible to realize the same effect as the depression symptom-improving effect of an electroconvulsive stimulation device, and the same effect as the depression symptom-improving effect and cognitive symptom-improving effect of a transcranial magnetic stimulation device, and can be used in a home environment when compared to electroconvusion stimulation devices and transcranial magnetic stimulation devices that are limited being used for treatment at a medical institution.

An ear vagus stimulator is characterized by comprising an ear electrode, a main frame and connection conductive wires; the main frame comprises a shell which is provided with a hook-shaped part in a protruding mode, the surface formed by the inner side face of the hook-shaped part and one side face of the shell together is matched with the outer side face of the ear back of the human body in shape, and therefore the main frame can be hung on the ear back of the human body; the ear electrode comprises an insulation base, an earplug electrode, an auricle electrode and a regulating knob, the earplug electrode plays a role in locating and acts on the ear canal port when the ear vagus stimulator is used, the auricle electrode plays a role in locating and acts on the auricle portion, the earplug electrode is fixedly arranged on the base, and the auricle electrode is connected to the base in a sliding mode; the regulating knob is screwed on the base, so that the auricle electrode is located on the base after sliding in place; the earplug electrode and the auricle electrode are connected to the main frame through the connection conductive wires. The ear vagus stimulator is simple in structure and convenient to carry, convenient and comfortable to operate when used, good in flexibility when used, and capable of adapting to the sizes and inner shapes of different ears.

The invention provides a probiotic composition and its application in the preparation of comorbid constipation and depression medicines, said composition comprising Bifidobacterium animalis subspecies U9, Lactobacillus paracasei L55, Lactobacillus rhamnosus LL23 , Bifidobacterium adolescentis BQ23 and Lactobacillus acidophilus RA15. The present invention has carried out a randomized double-blind test to perform probiotic intervention on depressed patients. A total of 63 depressed patients were recruited, 31 of whom had comorbid constipation. The results showed that after 8 weeks of intervention, the Hamilton depression (HAMD) score of the probiotic group decreased to 14.2±8.0 in the depressed group with comorbid constipation, which was significantly lower than that in the placebo group (22.9±9.9, P<0.05). There was no significant difference in HAMD scores between the population probiotic group and the placebo group. The probiotic composition of the invention can effectively alleviate the depression symptoms of depressed people with comorbid constipation.

The disclosure discloses the application of a 1-benzhydryl-4-methylpiperazine compound in the preparation of antidepressant drugs, which belongs to the field of medicine. The compound 1-benzhydryl-4-((1-benzene 1H-1,2,3-triazol-4-yl)methyl)piperazine can significantly improve the depression-like behavior in chronic unpredictable stress model mice. Mechanistic studies have shown that the compound 1‑benzhydryl‑4‑((1‑phenyl‑1H‑1,2,3‑triazol‑4‑yl)methyl)piperazine can improve the effects of chronic unpredictable stress Induced intestinal flora disturbance in mice; and has a protective effect on the integrity of the intestinal barrier and blood-brain barrier.